X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Africa

Roche Vitamins and Minerals Premix Plant, South Africa

Yuvraj_pawp by Yuvraj_pawp
6th September 2014
in Africa, Projects

Hoffman La Roche AG completed the construction of phase one of their new vitamins and minerals premix plant at Isando, in the Republic of South Africa, in June 2002. The facility was inaugurated by Dr Marcus Altwegg, head of Hoffman La Roche Vitamins and Fine Chemicals division, on 25 June 2002.

BUSINESS SOLD TO DSM

The business was sold to the Dutch chemicals firm DSM in late 2002, in a deal worth $2.24bn. Early in July 2002 Roche instigated negotiations with DSM for the sale of its entire vitamin and premix manufacturing business. Roche, along with other European companies, was fined in the US and Europe after being found guilty of operating a price-fixing cartel for vitamin and nutritional products.

“Roche was fined in the US and Europe after being found guilty of operating a price-fixing cartel for vitamin and nutritional products.”

The sale went ahead with closure of the deal in October 2003. The sale price negotiated was $2.24bn (€1.750m) and 2.24 million shares in DSM to be issued to Roche. Roche had dropped the price by €200m because of the legal issues surrounding price controlling and also retained liability for court costs and compensation arising from these legal issues.
Roche holds 42% market share worldwide in this business and is the world’s leading supplier of vitamins and carotenoids. DSM had no other vitamin and premix business interest and so avoided monopoly investigations by European government bodies.

ISANDO FACILITY

The facility manufactures vitamin premixes for the food and pharmaceutical industry in South Africa and surrounding African nations, such as Nigeria, Ghana and Kenya. The facility works in cooperation with UNICEF in producing the vitamin premixes necessary to fortify basic foodstuffs in under-developed African nations.

ISANDO PREMIX PLANT PROJECT

Construction of the premix plant at Isando was started in the first half of 2000. The new facility entered full commercial scale production a little later than first planned in 2002. The plant was constructed at an estimated cost of 30m Rand ($2.7m).

This facility was the first phase of a larger project. The subsequent phase, which was completed in early 2004, manufactures vitamin premixes for animal nutrition. The total value of the entire project is estimated at $6m. The capacity of the first phase facility was 1,400t/y. The much larger second phase took production to 3,000t/y by mid-2004.

THE PREMIX MARKET BURGEONS

In the pharmaceutical industry, vitamins are used in supplement preparations such as tablets or capsules. Since companies have begun moving away from using single vitamins to fortify their products and towards multiplicity, the services of premix plants have been in great demand. This has strengthened the premix industry considerably. It is for this reason that a number of premix plant projects have been initiated by leading pharmaceuticals suppliers. These include new Roche premix plants in Poland and at El Salto, Mexico. The company has a total of 48 premix facilities around the world.

Problems have arisen in the vitamins market in recent years due to increased competition from vitamin manufacturers in China who can produce cheaper products and also by the increasing cost of raw materials. The price increases are inevitably linked to the price of crude oil.

TEAVIGO: A RECENT SUCCESS IN SOUTH AFRICA

“DSM is looking to boost revenue by producing products from plant raw materials. A recent success story is Teavigo.”
DSM is looking to boost revenue by producing products from plant raw materials. A recent success story is Teavigo, which is a purified, concentrated form of the green tea active epigallocatechin gallate (EGCG) known as a potent antioxidant. This was developed by Roche prior to the sale to DSM.

Teavigo has achieved GRAS (generally regarded as safe) status from the US FDA and is now being incorporated into a wide range of foods. Prior to this the compound was incorporated into commercial food stuffs in South Africa.

COMBATING THE HIDDEN HUNGER PHENOMENON

Vitamin and mineral deficiencies prevent some 30% of the world’s population from achieving their full mental and physical potential. This phenomenon is often referred to as ‘hidden hunger’.

Food fortification is designed to combat the ‘hidden hunger’ problem by delivering foods rich in micronutrients to large populations, especially in developing countries. The plant at Isando can now produce the necessary vitamin A, B and mineral premixes to supplement basic foodstuffs and reduce the ‘hidden hunger’ problem. The plant is responsible for the supply of vitamins and nutritional mixes to its neighbouring countries in Africa.

Tags: Africa
Previous Post

AstraZeneca Solid Forms Production Plant, Cairo, Egypt

Next Post

DuBiotech, United Arab Emirates

Related Posts

Africa

Teva Announces New Organization Structure and Leadership Changes

27th November 2017
Africa

Rgenix Reports Phase 1a/B Clinical Data Demonstrating Immune-Stimulatory Activity With RGX-104

31st October 2017
Africa

Sancilio Pharma To Present An Update On Research In Sickle Cell At Upcoming National SCDAA Convention

31st October 2017
Europe

Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio® (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn’s Disease

30th October 2017
Africa

Arrakis Therapeutics Announces Release Of SHAPEware Bioinformatics Tools As Open-Source Software

24th October 2017
Africa

Avara pharmaceutical services acquires consumer healthcare facility from gsk in aiken, south carolina

21st September 2017
Next Post

DuBiotech, United Arab Emirates

Latest News

NIH begins study of allergic reactions to Covid-19 vaccines
News

To Treat COVID WHO Approves Monoclonal Antibody Tocilizumab

18th February 2022
Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In